^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mesmulogene ancovacivec (TG4010)

    i
    Associations
    News

    Trials

    Company:
    Transgene
    Drug class:
    Immunostimulant, IL-2 stimulant, MUC1 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) (NCT03353675)
    Phase 2
    Transgene
    Completed
    Last update posted :
    01/11/2022
    Initiation :
    01/05/2018
    Primary completion :
    11/20/2019
    Completion :
    02/17/2021
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • mesmulogene ancovacivec (TG4010)
    TG4010 and Nivolumab in Patients With Lung Cancer (NCT02823990)
    Phase 2
    Karen Kelly
    Completed
    Last update posted :
    10/13/2021
    Initiation :
    12/14/2016
    Primary completion :
    02/24/2021
    Completion :
    02/24/2021
    ALK
    |
    ALK mutation
    |
    Opdivo (nivolumab) • mesmulogene ancovacivec (TG4010)